Although salutary effects of PPARα and -γ agonists on memory have been reported in several preclinical AD models that overexpress APP, human clinical trials using PPARγ agonists in the treatment of AD are less encouraging (reviewed in refs. 10, 37). This evidence concerns the gene APP and Alzheimer disease.